Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest Valeant Pharmaceuticals Stories

2013-07-02 08:26:42

New physician loyalty program to include products from both companies LAVAL, Quebec, July 2, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced that Valeant's Medicis division, a leader in facial injectables and professional skin care, has formed a collaboration with Mentor Worldwide LLC, the U.S. market leader in breast aesthetics, to enter certain of their non-reimbursed products into a combined physician loyalty program. The new...

2013-06-24 08:29:04

LAVAL, Quebec, June 24, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) reports the closing of its recently priced public offering (the "Offering") of common shares and the exercise in full by the underwriters of their option to purchase additional common shares. The Company today issued 23,529,412 common shares at a price of $85.00 per share (the "Firm Shares") and, pursuant to the underwriters' exercise of their option to purchase...

2013-06-24 08:27:41

AURORA, ON, June 24, 2013 /CNW/ - Prollenium Medical Technologies Inc. is proud to announce the reacquisition of the rights to Ovita® HV, a hyaluronic based dermal filler. Ovita® is a high viscosity, non-animal based, biodegradable gel that treats deep and more pronounced lines and wrinkles, particularly oral commissures and nasolabial folds. The brand is produced by Prollenium and will be distributed worldwide. In 2010, Prollenium entered a partnership with international...

2013-06-20 08:26:37

LAVAL, Quebec, June 20, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) and (TSX: VRX) (the "Company") reports that the underwriters of its recently priced public offering of common shares (the "Offering") have exercised their option to purchase additional common shares and will purchase an additional 3,529,412 common shares at a price of $85.00 per share (the "Additional Shares"). The option to purchase Additional Shares was granted pursuant to the Offering of...

2013-06-18 20:21:27

LAVAL, Quebec, June 18, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) has priced its previously announced public offering of common shares (the "Offering"). Pursuant to the Offering, the Company will issue 23,529,412 common shares at a price of $85.00 per share, for aggregate gross proceeds of approximately $2.0 billion. The Company will file a final prospectus supplement to its effective shelf registration statement on Form S-3 and will...

2013-06-17 16:25:27

LAVAL, Quebec, June 17, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that it has filed a preliminary prospectus supplement to its effective shelf registration statement on Form S-3 and has today made a similar filing with securities regulatory authorities in each of the provinces of Canada in connection with a public offering of its common shares to raise gross proceeds of approximately $1.75 billion (the "Offering"). The Company...

2013-06-07 16:24:19

LAVAL, Quebec, June 7, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) announced today that it has filed a preliminary base shelf prospectus in Canada. The preliminary base shelf prospectus was filed with securities regulatory authorities in each of the provinces of Canada. Once receipts for the final base shelf prospectus are obtained from provincial securities regulators, the final base shelf prospectus will be valid for a 25-month period during which...

2013-05-28 08:33:06

HONG KONG, May 28, 2013 /PRNewswire/ -- Insiderslab.com is has released insider trading report for investors who invest in stocks of US: Procter & Gamble (NYSE:PG), Pfizer (NYSE:PFE), Valeant Pharmaceuticals (NYSE:VRX), Bank of America (NYSE:BAC), Exxon Mobil (NYSE:XOM), and Marvell (NASDAQ:MRVL). (Logo: http://photos.prnewswire.com/prnh/20100419/HKM001LOGO ) (Read full report by clicking the link below, you may need to copy and paste the full link to your browser.) Report...

2013-05-28 08:27:51

LAVAL, Quebec, May 28, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for efinaconazole for the treatment of onychomycosis. A CRL is issued by the FDA's Center for Drug Evaluation and Research when the review of a file is completed and questions remain that preclude the approval of the NDA in...

2013-05-27 08:21:18

Will Establish Valeant as a Global Leader in Eye Health as Well as Dermatology LAVAL, Quebec and ROCHESTER, N.Y., May 27, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) and Bausch + Lomb Holdings Incorporated, the global eye health company, today announced that they have entered into a definitive agreement under which Valeant will acquire Bausch + Lomb for $8.7 billion in cash. Bausch + Lomb is a leading global eye health company...